Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02295501 · ClinicalTrials.gov registry record · Phase 1
A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
A Phase 1 study, sponsored by Cerus Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02295501: Clinical Trial Phase 1 study, sponsored by Cerus Corporation.
NCT02295501 is a Phase 1 study that was terminated before completion, run by Cerus Corporation. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02295501, a Phase 1 study, was terminated before completion, sponsored by Cerus Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The objective of this Phase 1 safety study is to provide access to the potential therapeutic benefit of EBOV convalescent plasma containing antibodies to EBOV. The risk of exposure to plasma from donors who may be infected with other transfusion-transmitted pathogens, not detectable by current licensed donor testing procedures, will be mitigated by using pathogen inactivation to minimize the risk of the TTI from these donors, who would otherwise be deferred and ineligible for blood donation.
Interventions
- BIOLOGICAL INTERCEPT Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-12 |
| Est. Completion | 2020-12 |
| Phase | Phase 1 |
Why NCT02295501 stopped before completion
NCT02295501 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which INTERCEPT Plasma is the first listed.
NCT02295501 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02295501 about?
NCT02295501 is a clinical study titled "A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease". The objective of this Phase 1 safety study is to provide access to the potential therapeutic benefit of EBOV convalescent plasma containing antibodies to EBOV. The risk of exposure to plasma from donors who may be infected with other transfusion-transmitted pathogens, not detectable by current licen...
What is the current status of trial NCT02295501?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-12. Estimated completion is 2020-12.
What interventions are being tested in trial NCT02295501?
The interventions under investigation include: INTERCEPT Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT02295501?
This trial is sponsored by Cerus Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02295501's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia